Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc
Bullboard Posts
User Avatar Image
(31)
•••
Comment by stanleyon Nov 26, 2012 8:12am
155 Views
Post# 20642502

RE: SmarTrend Analysis...BRD Seriously Under d Rad

RE: SmarTrend Analysis...BRD Seriously Under d Rad

Kewl2:

 

RE:  "Brigus Gold ranks lowest with a forward P/E ratio of 5.36"

 

[S]: Is BRD under the radar or what? Patience will be rewarded as the $US reflects it's true long term value as:

1. The market awaits the audit of their gold reserves (the big story of alleged leasing for gold carry shorts ... Google)

 

2.  Shorting by warrant holders

 

3.  Uglification (BRD being held/kept under the radar until DR can bring Pearl 2 into production???)

 

4.  Company (T1, T2, hedge fund, etc) targeting BRD for take-over.

 

5. Market waiting for three positive quarters of increasing EPS.

 

5.1 Increasing WAUG grade and tonnes displacing OP grades below 2 gpt

 

6. The real reason ?????

 

BWDIK? CAVEAT EMPTOR .. we must be due for some in-fill drilling results by now?

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities